Based on the human genetic data and the promise of TL1A inhibition in non-clinical models, as well as the established efficacy of TNFα inhibitors in IBD, Amgen designed AMG 966, a TNFα/TL1A bi-specific immunoglobulin therapeutic candidate. Here, TNF is linked to inflammatory bowel disease.